The 2002 Women's Health Initiative scare made an entire generation of doctors afraid of hormone replacement therapy, and an entire generation of women started looking for alternatives. The data has shifted significantly since then. Modern HRT, used in the right patient at the right time, is much safer than the 2002 headlines suggested. But many women still want to manage perimenopause and menopause without it, and that is a legitimate choice. This is the honest review of the alternatives that actually have evidence, and the ones that mostly do not.
A note on HRT itself
Before discussing alternatives, it is worth being honest about HRT. The current evidence supports several conclusions that the 2002 headlines did not capture.
Transdermal oestradiol (the patch or the gel) avoids first-pass liver metabolism and has substantially lower risk of clotting than oral oestrogen. The clotting concerns from 2002 came largely from oral conjugated oestrogens, which are not the typical modern formulation.
For women who start HRT within ten years of menopause and below age 60, the cardiovascular and bone benefits typically outweigh the risks. Started later or in older women, the risk-benefit is less favourable.
For women who still have a uterus, oestrogen must be paired with progesterone or a progestin to protect the uterine lining. Micronised progesterone is the most physiological choice and has the cleanest side-effect profile.
Local vaginal oestrogen for genitourinary symptoms (dryness, recurrent UTIs, painful intercourse) is essentially without systemic risk and is often life-changing for the patients who need it.
So the first thing to say about HRT is that it is not snake oil and it is not poison. It is a tool. The right conversation is whether and when it fits a particular patient, not whether it should exist at all.
That said, many women do not want HRT, cannot use it, or prefer to try non-hormonal approaches first. Here is what the evidence says.
What works, with reasonable evidence
Resistance training, twice a week. The single most-supported non-pharmacological intervention for the perimenopause and menopause transition. Improves sleep, mood, body composition, bone density, insulin sensitivity, and quality of life. Cannot be replaced by walking. The evidence base is large and consistent.
Black cohosh (Cimicifuga racemosa). Has reasonable evidence for reducing hot flashes and night sweats, with effect sizes around 20-30% reduction in symptom severity. Dose typically 40-80 mg daily of standardised extract. Generally well-tolerated. Not recommended in patients with active liver disease.
Magnesium glycinate. 200-400 mg at night. Useful for sleep quality, muscle relaxation, and PMS symptoms. The evidence is strongest for sleep; the broader claims are less well-supported.
Cognitive behavioural therapy for hot flashes (CBT-HF). Specifically designed CBT protocols for vasomotor symptoms have evidence for meaningful symptom reduction. Less commonly used in India but available virtually.
Vitamin D, properly dosed. Supports bone, mood, and immune function during the transition. Push to above 50 ng/ml with sustained replacement.
Omega-3 fatty acids. 2 grams of EPA+DHA daily. Modest evidence for reducing depressive symptoms and joint stiffness.
Phosphatidylserine. 100-300 mg daily. Modest evidence for cortisol regulation and improving sleep in patients with elevated nighttime cortisol.
Mindfulness-based stress reduction. Reduces hot flash bother (the impact, more than the frequency) and improves quality of life. Well-supported.
What works for some patients but not all
Phytoestrogens (soy, red clover). Contain isoflavones that have weak oestrogenic activity. About 30-40% of patients report meaningful symptom improvement. Asian populations, who consume more dietary soy, often respond better. Safe in most patients, controversial in those with oestrogen-receptor-positive breast cancer history (though the evidence on harm is weak).
Maca root. Modest evidence for libido, mood, and energy. Effect sizes are not large but it is generally safe and well-tolerated. 1500-3000 mg daily of a standardised extract.
Ashwagandha. Used in Indian patients for stress, sleep, and energy. Modest evidence for cortisol modulation. Avoid in patients with active hyperthyroidism or thyroid medication adjustments in progress.
SSRIs and SNRIs (off-label for hot flashes). Low-dose paroxetine, venlafaxine, and others reduce hot flash frequency in non-HRT patients. Used by gynaecologists when HRT is contraindicated.
Gabapentin and clonidine. Older alternatives for vasomotor symptoms. Effective in some patients. Side effect burden often limits use.
Acupuncture. Mixed evidence. Some patients report meaningful improvement; trials have not consistently demonstrated benefit beyond placebo. Low-risk if available.
The middle ground is wider than most clinics let on. Real options exist. So do real placebos.
What mostly doesn't work, despite the marketing
Wild yam cream. Marketed as natural progesterone. The body cannot convert wild yam compounds into progesterone. The claims are false.
Most "menopause supplement blends". The combination products marketed in pharmacies and online typically contain modest doses of legitimate ingredients alongside fillers and unproven additives. Often expensive for what they deliver.
Bioidentical compounded hormone pellets. Marketed as safer and more natural than standard HRT. The evidence does not support these claims. The pellet form produces unpredictable hormone levels and is not the safer alternative it is sold as.
Generic adaptogens taken without context. Many adaptogens have legitimate uses in specific patients. Used as a generic perimenopause supplement, the effects are usually modest and inconsistent.
Cooling pillows and sprays. Help in the moment if hot flashes are mild. Not a treatment.
"Hormone balancing" diets. No specific dietary pattern reliably balances hormones in perimenopause. The principles that help (whole foods, adequate protein, fibre, fewer ultra-processed foods, alcohol moderation) help everyone. Branded "hormone diets" usually charge for the principles plus some unnecessary restriction.
How we actually use the alternatives
In our clinic, the typical perimenopause protocol layers in:
- Sleep, structurally addressed (foundation)
- Resistance training twice weekly (foundation)
- Protein at every meal (foundation)
- Magnesium glycinate at night (almost universal)
- Vitamin D properly dosed (almost universal)
- Black cohosh in patients with significant vasomotor symptoms who do not want HRT
- Targeted supplements based on the specific picture (phosphatidylserine, ashwagandha, omega-3, others)
- Mindfulness or CBT for patients with significant psychological distress
- Local vaginal oestrogen for genitourinary symptoms (often the biggest quality-of-life intervention)
- A real conversation about systemic HRT for patients with significant systemic symptoms who are within the appropriate window
We do not stack twelve supplements. We pick the three or four that match the patient's specific symptoms and labs.
The decision framework
Whether to use HRT, alternatives, or both is a personal decision shaped by several factors:
- Symptom severity and quality-of-life impact
- Time since menopause (HRT is most favourable when started within ten years of the final period)
- Personal and family history (cardiovascular, breast cancer, clotting, autoimmune)
- Patient preference and values
- What has been tried already and how it worked
A 38-year-old with disrupted sleep, mood lability, and increasing PMS may do well on lifestyle plus magnesium plus targeted supplements. A 49-year-old with severe hot flashes, night sweats, and joint pain may need a transdermal HRT conversation. A 55-year-old with vaginal dryness and recurrent UTIs may benefit from local vaginal oestrogen alone. The right answer is contextual.
What we do not do is pretend that one approach fits all, or that the alternatives are universally superior to HRT, or that HRT is dangerous when used appropriately.
The longer perimenopause pillar guide is the broader read on the transition.
